VivoSeq
Musculoskeletal

Myelopathy

15

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Myelopathy is an emerging landscape with 15 programs across 7 companies. The most active players are Tanabe Pharma Corporation, Roche, Kyowa Kirin Co., Ltd.. 3 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

70/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 1Roche logo

Roche

1 program

Phase 2Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 3S

Shanghai Hutchison Pharmaceuticals Limited

1 program

Phase 3A

Azurity Pharmaceuticals

1 program

Phase 3Gilead logo

Gilead

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

9 of 12 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody18%Peptide18%Cell therapy18%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

16

clinical trials

Completed7 · 44%
Unknown status3 · 19%
Terminated2 · 13%
Recruiting2 · 13%
Withdrawn1 · 6%
Active, not recruiting1 · 6%

Clinical Trials

Trial Activity

16 trials

Regeneration in Cervical Degenerative Myelopathy
Recruiting·—·Phase 3·NCT04631471·400 enrolled
Vagus Nerve Stimulation to Improve Post-operative Outcomes of Degenerative Cervical Myelopathy
Recruiting·WWashington University School of Medicine·Preclinical·NCT07660250·36 enrolled
Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy
Active, not recruiting·SShanghai Hutchison Pharmaceuticals Limited·Phase 3·NCT06377072·428 enrolled
Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)
Completed·AAOSpine North America Research Network·Phase 3·NCT01257828·270 enrolled
The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy
Completed·SSeoul National University Hospital·Phase 3·NCT02125981·160 enrolled
A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 1·NCT05240612·15 enrolled
Treatment of AIDS Vacuolar Myelopathy With Methionine
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00032695·56 enrolled
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00001785·12 enrolled
Long Term Follow-up of Cervical Myelopathy Inpatients Treated With Integrated Complementary and Alternative Medicine
Completed·JJaseng Medical Foundation·N/A·NCT04173923·40 enrolled
Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial
Completed·IImperial College London·Phase 2/3·NCT00272480·16 enrolled
A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)
Terminated·Kyowa Kirin Co., Ltd. logoKyowa Kirin Co., Ltd.·Phase 3·NCT03191526·66 enrolled
A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy
Terminated·—·Phase 4·NCT01561755·12 enrolled
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
Withdrawn·—·Phase 4·NCT01992562
Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy
Unknown status·UUniversity of Roma La Sapienza·Phase 4·NCT01052337·116 enrolled
Rituximab for HTLV-1-associated Myelopathy
Unknown status·FFirst Affiliated Hospital of Fujian Medical University·Phase 2·NCT04004819·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)